Related Experiment Video
Updated: May 14, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Hepatitis E virus seroprevalence and infection status among patients with inflammatory bowel disease undergoing
Dimitrije Damjanov1,2, Jelena Stojčević Maletić3,4, Tamaš Petrović5
1Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, Novi Sad, 21137, Serbia. dimitrije.damjanov@mf.uns.ac.rs.
Background:
Hepatitis E virus (HEV) is a significant cause of acute and chronic hepatitis, especially in immunosuppressed individuals. Patients with inflammatory bowel disease (IBD) undergoing advanced therapy may have an elevated risk of persistent HEV infection; however, evidence in this population is limited. This study evaluated HEV seroprevalence and infection status among IBD patients receiving advanced therapy in an endemic European region.
Methods:
In this prospective observational study, 142 adults with Crohn's disease (CD) or ulcerative colitis (UC) treated with advanced therapy between April 2024 and April 2025 were enrolled. Participants completed a structured questionnaire to assess HEV exposure risks and underwent testing for anti-HEV IgG and IgM antibodies as well as liver enzymes. HEV RNA in blood and stool samples was evaluated by real-time PCR in seropositive individuals.
Results:
Anti-HEV IgG antibodies were detected in 18.3% of participants, while all tested negative for anti-HEV IgM and HEV RNA, indicating no evidence of active or chronic infection. HEV seropositivity was significantly higher in patients with UC compared to those with CD (p = 0.031), but was not associated with demographics, disease characteristics, therapy type or duration, aminotransferase elevation, or assessed risk factors.
Conclusions:
HEV exposure among IBD patients receiving advanced therapy is similar to that observed in the general population, and chronic infection is uncommon. These findings suggest that routine HEV screening may not be necessary in all IBD patients receiving advanced therapy; however, this should be interpreted cautiously.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
Related Concept Videos
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...